Craft

Delcath Systems

Stock Price

$7.2

2024-05-15

Market Capitalization

$199.8 M

2024-05-15

Revenue

$2.1 M

FY, 2023

Delcath Systems Summary

Company Summary

Overview
Delcath Systems is an interventional oncology company which focuses on the treatment of primary and metastatic liver cancers. The Company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. 
Type
Public
Status
Active
Founded
1988
HQ
New York, NY, US | view all locations
Website
http://www.delcath.com
Cybersecurity rating
Sectors

Key People

  • Gerard Michel

    Gerard Michel, Chief Executive Officer

    • John Purpura

      John Purpura, Chief Operating Officer

      • Elizabeth Czerepak, Director

        • Gil Aharon, Director

          LocationsView all

          3 locations detected

          • New York, NY HQ

            United States

            Paramount Plaza, 1633 Broadway 22nd Floor, Suite C

          • Queensbury, NY

            United States

            566 Queensbury Ave

          • Galway

            Ireland

            Unit 19 Mervue Business Park

          Delcath Systems Financials

          Summary Financials

          Revenue (Q1, 2024)
          $3.1M
          Gross profit (Q1, 2024)
          $2.2M
          Net income (Q1, 2024)
          ($11.1M)
          Cash (Q1, 2024)
          $11.8M
          EBIT (Q1, 2024)
          ($10.3M)

          Footer menu